These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31734798)

  • 1. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
    Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
    Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.
    Kekäle M; Söderlund T; Koskenvesa P; Talvensaari K; Airaksinen M
    J Adv Nurs; 2016 Sep; 72(9):2196-206. PubMed ID: 27113362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
    de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
    Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital.
    Lee PM; Chang CT; Yusoff ZM
    Int J Clin Pharm; 2021 Feb; 43(1):46-54. PubMed ID: 32524510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
    Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
    Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
    Cole AL; Jazowski SA; Dusetzina SB
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
    Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
    Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.
    Sawicki C; Friend KE; Patel R; Polinski JM; Singh S
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1290-1296. PubMed ID: 31663460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
    Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
    J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
    Kim Y; Go TH; Jang J; Lee JB; Lim ST; Shim KY; Lee JI; Kong JH
    Korean J Intern Med; 2021 Nov; 36(6):1450-1458. PubMed ID: 34742178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
    Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.